TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8899091
Drug: Both low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Both low-dose and high-dose rINF-beta ser
Study: 25148243
Drug: Atomoxetine (20-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine (20-50 mg BID)
Study: 2180557
Drug: Allopurinol mouthwash
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Allopurinol mouthwash (20 mg)
Study: 26060991
Drug: Text messaging
Approvals — FDA: no, EMA: no, PMDA: no
Description: Text messaging interviews (administered by human interviewers)
Study: 26060991
Drug: Text messaging
Approvals — FDA: no, EMA: no, PMDA: no
Description: Text messaging interviews (administered by automated systems)
Study: 26060991
Drug: Voice interviews
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voice interviews (administered by human interviewers)
Study: 26060991
Drug: Voice interviews
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voice interviews (administered by automated systems)
Study: 19111849
Drug: IM aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IM aripiprazole 10 mg
Study: 19111849
Drug: IM aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IM aripiprazole (5 mg, 10 mg, or 15 mg)
Study: 17014022
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (amitriptyline and fluoxetine)
Study: 11090839
Drug: CT-1 antibody
Normalized name: CT-1
DrugBank: Cardiotrophin 1 (DB18399)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT-1 antibody
Study: 11090839
Drug: Ischemic preconditioning
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ischemic preconditioning (PC) with CT-1 antibody
Study: 9281254
Drug: CMF-chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMF-chemotherapy
Study: 8193733
Drug: Isradipine, 2.5
Normalized name: Isradipine, 2.5 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine, 2.5 mg twice daily
Study: 29508153
Drug: Ivabradine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivabradine + Beta-Blockers
Study: 29508153
Drug: Beta-Blockers Uptitration
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-Blockers Uptitration
Study: 27248464
Drug: SP loaded
Normalized name: SPS
Approvals — FDA: no, EMA: no, PMDA: no
Description: SP loaded nanostructured lipid carrier gel (SP-NLC)
Study: 27248464
Drug: SP loaded
Normalized name: SPS
Approvals — FDA: no, EMA: no, PMDA: no
Description: SP loaded alcoholic gel (SP-ALC)
Study: 11713152
Drug: Oral oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral oxygen delivery (45 patients)
Study: 24603565
Drug: No prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: No prescription
Study: 24603565
Drug: Delayed prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed prescription (recontact)
Study: 24603565
Drug: Delayed prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed prescription (post‐dated)
Study: 24603565
Drug: Delayed prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed prescription (collection)
Study: 24603565
Drug: Delayed prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed prescription (patient led)
Study: 23759464
Drug: Assertive specialized
Normalized name: epinephrine / mepivacaine hydrochloride Injectable Solution [Scandonest 2% Special]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assertive specialized treatment
Study: 21243757
Drug: L-carnitine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (1 g bid for 3 months before PESA-ICSI)
Study: 18440327
Drug: Erythropoietin (EPO)
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin (EPO) - single bolus of 60,000 IU administered within 3 hours of PCI
Study: 16832317
Drug: Methylphenidate (0.94
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (0.94 +/- 0.02 mg/kg/day = 33.06 +/- 1.40 mg/day)
Study: 12948399
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with interferon alpha‐2b (3 MU tiw) and ribavirin (1000‐1200 mg/day)
Study: 12948399
Drug: Ribavirin monotherapy
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin monotherapy (1000‐1200 mg/day)
Study: 12948399
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with interferon and ribavirin
Study: 12948399
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with interferon ribavirin
Study: 11049919
Drug: High-flow sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-flow sevoflurane anesthesia (6-10 L/min)
Study: 11049919
Drug: Low-flow isoflurane
Normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-flow isoflurane anesthesia (1 L/min)
Study: 1530165
Drug: Thiopental with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental with fentanyl (n = 18, fentanyl concentration 1.27 +/- 0.5 ng/mL)
Study: 3911613
Drug: Liquid dimeticon
Normalized name: dimethicone Medicated Liquid Soap
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid dimeticon preparation (480 mg over 24 hours)
Study: 31621671
Drug: Low-dose dexamethasone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dexamethasone
Study: 26362826
Drug: Caucasian whortleberry
Normalized name: whortleberry substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caucasian whortleberry (1 g/day) for 90 days
Study: 26362826
Drug: Cinnamon (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinnamon (1 g/day) for 90 days
Study: 25168404
Drug: IV fluid
Normalized name: IV fluid
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV fluid (10 mL/kg IV 0.9% sodium chloride) with no expectation of medication (Group A)
Study: 25168404
Drug: IV fluid
Normalized name: IV fluid
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV fluid (10 mL/kg IV 0.9% sodium chloride) with expectation of medication (Group B)
Study: 23257008
Drug: Tetrandrine tablets
DrugBank: Tetrandrine (DB14066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetrandrine tablets (100 mg bid) and matrine injection (150 mg qd)
Study: 23257008
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (anti-inflammatory, cough-relieving, and anti-asthmatic treatment only)
Study: 23257008
Drug: Tetrandrine tablets
DrugBank: Tetrandrine (DB14066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetrandrine tablets combined with matrine injection
Study: 11783199
Drug: Step respiration
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Step respiration exercise (SRE) combined with Chinese drug therapy (CDT)
Study: 11783199
Drug: Chinese drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese drug therapy (CDT)
Study: 7860833
Drug: Signal detection
Normalized name: alpha tocopherol / ascorbic acid / cholecalciferol / docosahexaenoic acid / docusate sodium / ferrous fumarate / folic acid / pyridoxine hydrochloride / tricalcium phosphate Oral Capsule [Nexa Select]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Signal detection model applied to Japanese listeners' /r/-/l/ labeling behavior
Study: 2045865
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human IL-3 (daily 4-hour intravenous infusion for 28 days at doses of 30, 60, 125, 250, 500, 750, and 1,000 micrograms/m2/d)
Study: 6941447
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose and two doses of intravenous metronidazole (500 mg/100 ml)
Study: 6941447
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of intravenous metronidazole (500 mg/100 ml) with placebo (100 ml normal saline)
Study: 6941447
Drug: Placebo (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (100 ml normal saline) for both doses
Study: 23857339
Drug: Satisfaction with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Satisfaction with treatment
Study: 19957797
Drug: Heparin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin treatment group (n = 37)
Study: 19957797
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment group (n = 42)
Study: 17520105
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of low-dose atorvastatin (5 mg/day) and fenofibrate (160 mg/day)
Study: 17520105
Drug: Fenofibrate (160-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate (160-200 mg/day)
Study: 15339323
Drug: Topical 0.1
Normalized name: adapalene topical 0.1% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.1 n hydrochloric acid
Study: 11336714
Drug: 400 microg
Normalized name: Fentanyl 400 microgram buccal film
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 microg rectal misoprostol in 5 cm(3) of saline
Study: 6393724
Drug: High-dose betamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose betamethasone for 4-5 days
Study: 30674279
Drug: Previous experiences
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Previous experiences of pain medication
Study: 30674279
Drug: Understanding of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Understanding of pain medication
Study: 28834103
Drug: Autologous platelet-rich
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous platelet-rich plasma (PRP) weekly for 6 weeks
Study: 28834103
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (compression and dressing) for 6 weeks
Study: 22551551
Drug: LR17 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LR17 treatment (early or late)
Study: 19663922
Drug: Glucose (BD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose (BD Glucose Tablets)
Study: 10597985
Drug: Placebo (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (single high dose every 4 months)
Study: 8565034
Drug: Mepyramine-theophylline-acetate (MTA)
Normalized name: ambroxol-theophylline-7-acetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepyramine-theophylline-acetate (MTA) 8 mg/kg per day by mouth in three divided doses for 7 days
Study: 8565034
Drug: Placebo 50
Normalized name: placebo 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 50 microL/kg per day in three divided doses for 7 days
Study: 31406997
Drug: Basal diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal diet with 500 mg/kg resveratrol (HT+Res)
Study: 29315807
Drug: Religion prime
Normalized name: Ficus religiosa leafy twig extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Religion prime administered to atheists
Study: 24625704
Drug: 1-Hz rTMS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-Hz rTMS over the right dorsolateral prefrontal cortex (intensity of 110% of the threshold; 3000 stimuli per protocol; 10 daily sessions) combined with partial sleep deprivation (PSD applied once per week)
Study: 23171380
Drug: Rhythm and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhythm and music-based therapy program
Study: 9973914
Drug: iodixanol (Visipaque)
Normalized name: Iodixanol
DrugBank: Iodixanol (DB01249)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: iodixanol (Visipaque) 270 mg I/ml
Study: 9973914
Drug: iopamidol (Iopamiron)
Normalized name: Iopamidol
DrugBank: Iopamidol (DB08947)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: iopamidol (Iopamiron) 300 mg I/ml
Study: 1689084
Drug: Epidural administration
Normalized name: epidural administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural administration of endogenous opioids
Study: 1689084
Drug: Intrathecal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal administration of endogenous opioids
Study: 7028529
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium (about 75 mg daily)
Study: 24519844
Drug: Subcutaneous drainage
Normalized name: PLEURX DRAINAGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous drainage (10 Fr drain placed subcutaneously connected to low pressure aspiration reservoir)
Study: 24519844
Drug: No subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: No subcutaneous drainage (control group)
Study: 24519844
Drug: Subcutaneous drainage
Normalized name: PLEURX DRAINAGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous drainage
Study: 24519844
Drug: No subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: No subcutaneous drainage
Study: 16217662
Drug: 0.7% dexamethasone‐cyclodextrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.7% dexamethasone‐cyclodextrin eye drop solution applied once daily
Study: 8651235
Drug: Self-reported drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-reported drug injection behaviors
Study: 6137292
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (single-vessel disease)
Study: 6137292
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy (single-vessel disease)
Study: 6137292
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (double-vessel disease)
Study: 6137292
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy (double-vessel disease)
Study: 6137292
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (triple-vessel disease)
Study: 6137292
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy (triple-vessel disease)
Study: 6137292
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (ejection fraction ≥ 0.50, single-vessel disease)
Study: 6137292
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy (ejection fraction ≥ 0.50, single-vessel disease)
Study: 6137292
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (ejection fraction ≥ 0.50, double-vessel disease)
Study: 6137292
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy (ejection fraction ≥ 0.50, double-vessel disease)
Study: 6137292
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (ejection fraction ≥ 0.50, triple-vessel disease)
Study: 6137292
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy (ejection fraction ≥ 0.50, triple-vessel disease)
Study: 6137292
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment (initially assigned)
Study: 30947751
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg iron dextran (Cosmofer)
Study: 30947751
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg iron sucrose (Venofer)
Study: 30947751
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg iron isomaltoside (Monofer)
Study: 30947751
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg iron isomaltoside (Monofer)
Study: 30947751
Drug: All iron
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All iron preparations
Study: 29135863
Drug: Bone-Anchored Implants
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone-Anchored Implants (BAI)
Study: 20825805
Drug: Phenobarbital (PB)
Normalized name: Phenobarbital
DrugBank: Phenobarbital (DB01174)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbital (PB) - mean dosage 509 mg
Study: 20825805
Drug: Lorazepam (LZ)
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lorazepam (LZ) - mean dosage 4.2 mg
Study: 9467701
Drug: Tailored antihypertensive
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored antihypertensive educational intervention
Study: 29445029
Drug: Pantoprazole (IV,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole (IV, 1.6 mg/kg over 4 hours) with Cisplatin (60 mg/m2 × 2 days per cycle)
Study: 29445029
Drug: Cisplatin (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (60 mg/m2 × 2 days per cycle) without Pantoprazole
Study: 29445029
Drug: Pantoprazole (IV,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole (IV, 1.6 mg/kg over 4 hours) with Cisplatin
Study: 24726032
Drug: Ongoing low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ongoing low molecular weight heparin treatment for cancer-associated thrombosis
Study: 24726032
Drug: Cessation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cessation of low molecular weight heparin at six months treatment (current licensed practice)
Study: 22994901
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg cyproheptadine (5‐HT antagonist)
Study: 22994901
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg escitalopram (SSRI)
Study: 14498766
Drug: Atlizumab (anti-IL-6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atlizumab (anti-IL-6 receptor antibody)
Study: 10875526
Drug: 1,25‐dihydroxy‐cholecalciferol vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,25‐dihydroxy‐cholecalciferol vitamin D (0.25 mcg daily) and calcium (500 mg daily) for 9 months
Study: 9170524
Drug: PFL-therapy (CDDP,
Approvals — FDA: no, EMA: no, PMDA: no
Description: PFL-therapy (CDDP, 5-FU, and dl-LV)
Study: 9170524
Drug: FL-therapy (5-FU
Approvals — FDA: no, EMA: no, PMDA: no
Description: FL-therapy (5-FU and dl-LV)
Study: 1437426
Drug: Mailed poisoning
Normalized name: poison ivy extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mailed poisoning prevention packet (telephone stickers, coupon for syrup of ipecac, cabinet lock, checklist, pamphlets, cover letter)
Study: 26946313
Drug: Intravenous ascorbic
Normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ascorbic acid infusion (2g administered starting 30 minutes before anesthesia for 2 hours)
Study: 26946313
Drug: Placebo (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (administered starting 30 minutes before anesthesia for 2 hours)
Study: 26946313
Drug: Intravenous ascorbic
Normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ascorbic acid infusion
Study: 24792937
Drug: Cephalexin, 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalexin, 500 mg (every 6 hours for 7 days)
Study: 24792937
Drug: Clindamycin, 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin, 300 mg (every 6 hours for 7 days)
Study: 15139775
Drug: ITF-1697 dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: ITF-1697 dose 2 (loading dose 110 microg/kg i.v., infusion 1.0 microg/kg/min for 24 hours)
Study: 15139775
Drug: ITF-1697 dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: ITF-1697 dose 1 (loading dose 55 microg/kg i.v., infusion 0.5 microg/kg/min for 24 hours)
Study: 9755357
Drug: Long-term maintenance
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term maintenance treatment for recurrent unipolar major depression; specific intervention details not provided.
Study: 9755357
Drug: Continuation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuation treatment of major depression; specific intervention details not provided.
Study: 7736899
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of glucose with model assessment (CIGMA)
Study: 7736899
Drug: Hyperglycaemic clamp
Normalized name: CLAMP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperglycaemic clamp (10 mmol/l)
Study: 169104
Drug: Aminosidin-polymyxin B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminosidin-polymyxin B combination
Study: 31177183
Drug: GOP infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GOP infusion
Study: 27053635
Drug: Baseline MRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline MRI parameters (T2 lesion number, T1 and T2 lesion volumes, corpus callosum (CC), thalamic fraction)
Study: 27053635
Drug: 12-month MRI
Normalized name: moth bean
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-month MRI parameters (Expanded Disability Status Scale (EDSS), number of new or enlarging T2 lesions, CC volume % change)
Study: 25637266
Drug: Edivoxetine (EDX)
Normalized name: EDX-502
DrugBank: Edivoxetine (DB09184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edivoxetine (EDX) 6 mg or 9 mg once daily for 14 or 15 days
Study: 25637266
Drug: Atomoxetine (ATX)
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atomoxetine (ATX) 80 mg once daily for 14 or 15 days
Study: 24102571
Drug: Dexmedetomidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (1 μg kg(‐1) over 10 minutes, followed by 0.4 μg kg(‐1)h(‐1) for 60 minutes)